Optimizing Therapy for Endometrial Cancer: Recent Data Highlights - Episode 10

Revolutionizing Frontline Therapy for Endometrial Cancer: Checkpoint Inhibitors and MMR Status

,

Explore the groundbreaking shift in frontline treatment for endometrial cancer, driven by recent data from trials like RUBY and GY018, highlighting the significant impact of checkpoint inhibitors in patients with mismatch repair deficiency.

EP. 1: Changing Landscape of Endometrial Cancer: Incidence and Classification
EP. 2: Optimal Workup Strategies in Advanced Endometrial Cancer
EP. 3: Factors in Frontline Treatment Decision Making for Endometrial Cancer
EP. 4: Assessing Response to First-Line Therapy in Advanced Endometrial Cancer: Clinical Factors
EP. 5: Chronic Challenges in Endometrial Cancer: Recurrence and Second-Line Therapy
EP. 6: Treatment Choices for Recurrent dMMR Endometrial Cancer
EP. 7: HER2-Positive Endometrial Cancer: A Targeted Approach to Treatment
EP. 8: Treatment for Recurrent Endometrial Cancer: Chemotherapy or Lenvatinib + Pembrolizumab
EP. 9: Endometrial Cancer: Managing Toxicities in Lenvatinib and Pembrolizumab
Now Viewing
EP. 10: Revolutionizing Frontline Therapy for Endometrial Cancer: Checkpoint Inhibitors and MMR Status
EP. 11: Expanding Horizons in Endometrial Cancer Treatment: Beyond Chemotherapy
EP. 12: Diversity and Access to Clinical Trials in Endometrial Cancer